Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 03/27/23
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of DirectorsBusiness Wire • 02/24/23
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration AgreementsBusiness Wire • 12/14/22
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 11/14/22
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic AlternativesBusiness Wire • 09/26/22
Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines ConferenceBusiness Wire • 09/01/22
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate ProgressBusiness Wire • 08/15/22
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock SplitBusiness Wire • 06/29/22
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences ConferenceBusiness Wire • 05/17/22
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate ProgressBusiness Wire • 05/16/22
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market PremiumBusiness Wire • 05/10/22
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics ConferenceBusiness Wire • 05/09/22
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate ProgressBusiness Wire • 03/25/22
Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?Newsfile Corp • 02/17/22
